Tech Company Financing Transactions

CRISPR Therapeutics Funding Round

Celgene, SR One Capital Management and Abingworth invested in a $64 million Series B venture round for CRISPR Therapeutics. The round closed on 4/30/2015.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

610 Main St.
Cambridge, MA 02139
USA

Phone

(617) 315-4600

Website

www.crisprtx.com

Email Address

[email protected]

Overview

The mission of CRISPR Therapeutics (Nasdaq: CRSP) is to develop transformative gene-based medicines for patients with serious diseases. Our therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called CRISPR-Cas9.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Samarth Kulkarni

        

President

Rodger Novak

        

VP - Bus. Development

Lawrence Klein

        

VP - General Counsel

James Kasinger

        

VP - Human Resources

Megan Menner

        

VP - R & D

Tony Ho

        

Browse more venture capital transactions:

Prev: 4/30/2015: PlateJoy venture capital transaction
Next: 4/30/2015: ThreatQuotient venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. All VC database entries reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary